William Savage
Chief Tech/Sci/R&D Officer at DISC MEDICINE, INC.
Net worth: 3 M $ as of 31/03/2024
Profile
William Savage is currently the Chief Medical Officer at Disc Medicine Opco, Inc. and Disc Medicine, Inc. He previously worked as the Associate Medical Director at The Johns Hopkins University School of Medicine, Senior Medical Director at Magenta Therapeutics, Inc., Assistant Professor at The Brigham & Women's Hospital, Inc., Assistant Professor at Harvard Medical School, and Chief Medical Officer at Gemini Therapeutics, Inc. Dr. Savage completed his undergraduate degree at The Trustees of Columbia University in The City of New York and obtained doctorate degrees from Weill Cornell Medical College and Johns Hopkins Bloomberg School of Public Health.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
DISC MEDICINE, INC.
0.18% | 10/04/2024 | 43,405 ( 0.18% ) | 3 M $ | 31/03/2024 |
William Savage active positions
| Companies | Position | Start |
|---|---|---|
| DISC MEDICINE, INC. | Chief Tech/Sci/R&D Officer | 01/08/2020 |
Disc Medicine Opco, Inc.
 Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 01/08/2020 |
Former positions of William Savage
| Companies | Position | End |
|---|---|---|
| MAGENTA THERAPEUTICS | Chief Tech/Sci/R&D Officer | 01/07/2020 |
The Brigham & Women's Hospital, Inc.
 The Brigham & Women's Hospital, Inc. Hospital/Nursing ManagementHealth Services The Brigham & Women's Hospital, Inc. provides health care services. The firm offers treatment for cancer, cardio vascular, neurosciences, orthopedic, arthritis, women's health and clinical services. The company was founded in 1980 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01/01/2017 |
| The Johns Hopkins University School of Medicine | Corporate Officer/Principal | - |
| Harvard Medical School | Corporate Officer/Principal | - |
| GEMI THER | Chief Tech/Sci/R&D Officer | - |
Training of William Savage
| The Trustees of Columbia University in The City of New York | Undergraduate Degree |
| Weill Cornell Medical College | Doctorate Degree |
| Johns Hopkins Bloomberg School of Public Health | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| DISC MEDICINE, INC. | Health Technology |
| Private companies | 4 |
|---|---|
The Brigham & Women's Hospital, Inc.
The Brigham & Women's Hospital, Inc. Hospital/Nursing ManagementHealth Services The Brigham & Women's Hospital, Inc. provides health care services. The firm offers treatment for cancer, cardio vascular, neurosciences, orthopedic, arthritis, women's health and clinical services. The company was founded in 1980 and is headquartered in Boston, MA. | Health Services |
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | Health Technology |
Gemini Therapeutics, Inc.
 Gemini Therapeutics, Inc. BiotechnologyHealth Technology Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. It is developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration. The company was founded by Johanna Seddon, Paul Barlow and Andrew Herbert on March 3, 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- William Savage
